Curida to Manufacture PCI Biotech’s Amphinex

July 22, 2016
Pharmaceutical Technology Editors

Curida will manufacture PCI Biotech’s Amphinex, a drug used to treat bile duct cancer.

On July 1, 2016, Curida and PCI Biotech entered into an agreement to manufacture Amphinex, PCI’s lead product candidate. Amphinex is undergoing international clinical trials for bile duct cancer, Curida said in a press announcement. Entering into partnerships with biotech companies at an early stage is part of Curida’s long-term growth strategy, Leif Rune Skymoen, CEO of Curida, noted in a press announcement. 

Curida is located in Elverum, Norway and offers contract manufacturing, development, and laboratory services, primarily for large and small companies in the pharmaceutical sector. Curida and PCI Biotech are co-located at the Oslo Cancer Cluster Incubator, which facilitates the research and development of new cancer treatments. 

Source: Curida

 

Related Content:

PharmTech News | Supplier News